IDH1 and IDH2 control the methylation status; found in 7–19% of AMLs, IDH2 represents now an optimal target for enasidenib that offers 40% of responses to relapsed/refractory AML patients [46, 47]. This evidence concerns the gene IDH2 and acute myeloid leukemia.